Sign in

    Daniel A. Carestio

    President and CEO at STERIS plc
    Since July 1, 2021
    Age
    51 years
    Tenure
    Joined STE in August 2015 and held various roles including Senior Vice President, Sterilization and Disinfection; Senior Vice President, STERIS Applied Sterilization Technologies (AST) and Life Sciences; and Senior Vice President and Chief Operating Officer before being promoted to President and CEO in July 2021.

    Also at STERIS plc

    AX
    Andrew Xilas
    Senior Vice President and General Manager, Dental
    CLM
    Cary L. Majors
    Senior Vice President and President, Healthcare
    JAZ
    J. Adam Zangerle
    Senior Vice President, General Counsel, and Secretary

    About

    Daniel A. Carestio, aged 51 as of March 31, 2024 , has exhibited a strong record of leadership at STE. His tenure in the organization reflects a dedication to operational excellence and strategic growth, developed over several progressive roles.

    He began his journey with STE in August 2015 as Senior Vice President, STERIS Applied Sterilization Technologies (AST) and Life Sciences, before moving into roles as Senior Vice President, Sterilization and Disinfection and later as Senior Vice President and Chief Operating Officer. His rise within the company highlights his deep understanding of the healthcare and sterilization industries, as well as his ability to manage complex operations.

    In July 2021, he was promoted to President and CEO, marking a significant milestone in his career. His leadership has been instrumental in guiding the company through industry challenges and leveraging his extensive experience to enhance its operational capabilities and strategic direction.

    $STE Performance Under Daniel A. Carestio

    Past Roles

    OrganizationRoleDate Range
    STERIS Senior Vice President and Chief Operating Officer August 2018 – July 2021
    STERIS Senior Vice President, Sterilization and Disinfection February 2018 – July 2018
    STERIS Senior Vice President, STERIS Applied Sterilization Technologies (AST) and Life Sciences August 2015 – February 2018

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary$1,030,600 Regular salary paid during fiscal 2024Represents a 6.26% increase from fiscal 2023’s base salary of $969,862
    All Other Compensation$11,987 Paid concurrently with base salaryPrimarily includes employer matching contributions to the 401(k) plan, including an employer contribution of $11,957

    Performance Compensation

    Data from  FY 2024

    Annual Incentive Compensation (Cash Bonus)

    MetricDetail
    Target Bonus Percentage125.0% of base salary
    Base Salary$1,030,600
    Bonus Range0% to 200% of the target bonus
    Performance MetricBased on financial performance measures (EBIT and Free Cash Flow)
    Achievement Level87.2% aggregate financial achievement
    Actual Payout Amount$1,123,539 at an achievement level of 87.2%
    Evaluation PeriodFiscal 2024
    Additional ConditionsCommittee may modify based on personal objectives; bonus levels are aligned with peer company medians

    No vesting schedule applies since this is a cash bonus incentive.